Francesco Forconi (MD, DM, PhD, FRCPath) is a Professor of Haematology and leader of the academic Cancer B-cell Group, comprising world-class scientists investigating the pathogenesis and clinical behavior of lymphomas and chronic lymphocytic leukemia at the University of Southampton, UK. His most recent investigations have expanded around the cancer-specific post-translation modifications (oligomannose-type glycans) of the B-cell receptor of germinal center lymphomas and how to target therapeutically their interaction with microenvironmental lectins in follicular lymphoma. His clinical activity is primarily dedicated to the care of patients with lymphomas and CLL, leading the CLL Service and a broad portfolio of interventional clinical trials. He is the UK lead of the international CRUK ECRIN-M3 consortium, investigating the early diagnosis of leukemias and lymphomas with partnerships in Europe, South America, and Africa. He has been a Member of the UK NCRI Haematological Oncology Clinical Studies Group and continues to be an active member of the UK NCRI CLL subgroup. He has served NICE UK for several appraisals of novel agents in clinical practice. He is a core member of the International HCL Foundation, USA and leads Southampton as a “Center of Excellence” for HCL. He is Editorial Board Member for BLOOD and contributes as a reviewer for the major journals and conferences of hematology. He is currently the author of >150 peer-reviewed publications.